NFKB1 and pancreatic neoplasm: Furthermore, conventional chemotherapeutics like gemcitabine or paclitaxel are often associated with high resistance rates in pancreatic neoplasms, which is partly due to a constitutively activated RelA/NF-κB pathway [15,33].